Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021 Background Sacubitril/Valsartan has been highly efficacious in randomized trials of heart failure with reduced ejection fraction (HFrEF). However, the effectiveness of sacubitril/valsartan in older patients hospitalized for HFrEF in real‐world US ...
Stephen J. Greene +16 more
doaj +1 more source
Randomized multicentre pilot study of sacubitril/valsartan versus irbesartan in patients with chronic kidney disease: United Kingdom Heart and Renal Protection (HARP)- III—rationale, trial design and baseline data [PDF]
, 2016 BACKGROUND: Patients with chronic kidney disease (CKD) are at risk of progression to end-stage renal disease and cardiovascular disease. Data from other populations and animal experiments suggest that neprilysin inhibition (which augments the ...
Baigent, C. +23 more
core +4 more sources
Potential of valsartan+sacubitril therapy in hypertensive heart disease
Российский кардиологический журнал, 2021 The course of hypertension is often complicated by left ventricular hypertrophy (or hypertensive heart disease, HHD). The main “corridor” of natural HHD is development of heart failure with preserved ejection fraction (HFpEF).
A. G. Ovchinnikov +4 more
doaj +1 more source
Sacubitril Ameliorates Cardiac Fibrosis Through Inhibiting TRPM7 Channel
Frontiers in Cell and Developmental Biology, 2021 Heart failure caused by cardiac fibrosis has become a major challenge of public health worldwide. Cardiomyocyte programmed cell death (PCD) and activation of fibroblasts are crucial pathological features, both of which are associated with aberrant Ca2 ...
Tian Jia +9 more
doaj +1 more source
Resetting the neurohormonal balance in heart failure (HF). the relevance of the natriuretic peptide (NP) system to the clinical management of patients with HF [PDF]
, 2017 The natriuretic peptide (NP) system, which includes atrial natriuretic peptide, B-type natriuretic peptide, and C-type natriuretic peptide, has an important role in cardiovascular homeostasis, promoting a number of physiological effects including ...
Rubattu, Speranza Donatella +1 more
core +2 more sources
Effect of sacubitril/valsartan on recurrent events in the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF) [PDF]
, 2018 Aims: Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs.
Abraham +18 more
core +3 more sources
Influence of Sacubitril/Valsartan (LCZ696) on 30-day readmission after heart failure hospitalization [PDF]
, 2016 Background: Patients with heart failure (HF) are at high risk for hospital readmission in the first 30 days following HF hospitalization. Objectives: This study sought to determine if treatment with sacubitril/valsartan (LCZ696) reduces rates ...
Claggett, Brian L. +11 more
core +2 more sources
Acta Pharmaceutica, 2021 Our study evaluates the effects of sacubitril/valsartan (SAC/VAL) in the rabbit model of doxorubicin-induced heart failure. Twenty rabbits (5 per group) were administered with doxorubicin (DOX, 1.5 mg kg−1, i.v.) to induce heart failure.
Yu Chun +4 more
doaj +1 more source
Risk related to pre–diabetes mellitus and diabetes mellitus in heart failure with reduced ejection fraction: insights from prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial [PDF]
, 2016 Background—The prevalence of pre–diabetes mellitus and its consequences in patients with heart failure and reduced ejection fraction are not known.
Cardoso, José Silva +17 more
core +1 more source
Molecules, 2021 The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with cardioprotective properties.
Pema Raj +6 more
doaj +1 more source